Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392333 · ClinicalTrials.gov registry record
A Prospective Cohort Study of Basivertebral Nerve Ablation Using the Stryker OptaBlate BVN System for the Treatment of Vertebrogenic Low Back Pain
A clinical trial, sponsored by Stryker Instruments.
- Recruiting
- Registry status
- 25
- Enrollment target
NCT07392333: Recruiting study, sponsored by Stryker Instruments.
NCT07392333 is a clinical trial that is actively recruiting participants, run by Stryker Instruments. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07392333 is actively recruiting participants, sponsored by Stryker Instruments.
- RECRUITING
- Registry status
- 25 participants
- Enrollment target
Study Summary
The goal of this observational study is to evaluate patient outcomes following treatment of vertebrogenic low back pain using the Stryker OptaBlate BVN System. Patients treated in accordance with the device IFU as part of routine clinical care and who consent to participate will be followed for 12 months after the procedure to assess treatment outcomes.
Interventions
- DEVICE Basivertebral nerve ablation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2027-11-30 |
What NCT07392333 shows while recruiting
NCT07392333 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Basivertebral nerve ablation is the first listed.
NCT07392333 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07392333 about?
NCT07392333 is a clinical study titled "A Prospective Cohort Study of Basivertebral Nerve Ablation Using the Stryker OptaBlate BVN System for the Treatment of Vertebrogenic Low Back Pain". The goal of this observational study is to evaluate patient outcomes following treatment of vertebrogenic low back pain using the Stryker OptaBlate BVN System. Patients treated in accordance with the device IFU as part of routine clinical care and who consent to participate will be followed for 12 m...
What is the current status of trial NCT07392333?
This trial is currently recruiting. The enrollment target is 25 participants. The study started on 2026-06-02. Estimated completion is 2027-11-30.
What interventions are being tested in trial NCT07392333?
The interventions under investigation include: Basivertebral nerve ablation (DEVICE).
Who is sponsoring clinical trial NCT07392333?
This trial is sponsored by Stryker Instruments, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI